title: Comparison of change in coronary atherosclerosis in patients with stable versus unstable angina pectoris receiving statin therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] study).
abstract: Although statin-induced regression in coronary atherosclerosis seems to be greater in patients with acute coronary syndrome than in those with stable coronary artery disease, no reports have examined this. The purpose of the present study was to compare the changes in coronary atherosclerosis in patients with stable versus unstable angina pectoris (AP). The effects of 8-month statin therapy on coronary atherosclerosis were evaluated using virtual histology intravascular ultrasound, and analyzable intravascular ultrasound data were obtained from 119 patients (83 patients with stable AP and 36 with unstable AP). A significant decrease in plaque volume was observed in patients with unstable AP (-2.2%, p = 0.02) but not in patients with stable AP. A significant increase in the necrotic-core component (0.30 mm(3)/mm, p = 0.009) was observed only in patients with unstable AP. Significant positive correlations were observed between the percentage of change in platelet-activating factor acetylhydrolase and the percentage of change in plaque volume (r = 0.346, p = 0.05) in patients with unstable AP. No significant correlations were observed in patients with stable AP. Multivariate regression analyses showed that a reduction in platelet-activating factor acetylhydrolase was associated with regression in coronary atherosclerosis, particularly of the fibrous component (β = 0.443, p = 0.003), in patients with unstable AP. In conclusion, regression of the coronary artery plaque volume was greater, although statin therapy did not halt the increases in plaque vulnerability, in patients with unstable AP compared to those with stable AP. A reduction in the serum platelet-activating factor acetylhydrolase level was associated with regression in coronary atherosclerosis, particularly the fibrous plaque volume, in patients with unstable AP.
authors: Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Yokohama, Japan. nozue2493@yahoo.co.jp
authors: Tsuyoshi
authors: T
authors: Nozue
authors: Shingo
authors: S
authors: Yamamoto
authors: Shinichi
authors: S
authors: Tohyama
authors: Kazuki
authors: K
authors: Fukui
authors: Shigeo
authors: S
authors: Umezawa
authors: Yuko
authors: Y
authors: Onishi
authors: Tomoyuki
authors: T
authors: Kunishima
authors: Akira
authors: A
authors: Sato
authors: Toshihiro
authors: T
authors: Nozato
authors: Shogo
authors: S
authors: Miyake
authors: Youichi
authors: Y
authors: Takeyama
authors: Yoshihiro
authors: Y
authors: Morino
authors: Takao
authors: T
authors: Yamauchi
authors: Toshiya
authors: T
authors: Muramatsu
authors: Kiyoshi
authors: K
authors: Hibi
authors: Mitsuyasu
authors: M
authors: Terashima
authors: Ichiro
authors: I
authors: Michishita
mesh_terms: D000368:Aged; D060050:Angina, Stable / Q000150:complications*; D000789:Angina, Unstable / Q000150:complications*; D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007564:Japan; D008055:Lipids / Q000097:blood; D008297:Male; D058226:Plaque, Atherosclerotic / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D017035:Pravastatin / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D012044:Regression Analysis; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011804:Quinolines; D017035:Pravastatin; C108475:pitavastatin